Jaguar Health, Inc. (NASDAQ:JAGX) went up to recover about 37.83% since recording its record low price of $0.12. The stock experienced -4.23% slump, arriving at $0.16 on 3/14/2019. During the day, the stock price traveled from $0.15 to $0.1654. This company shares are 681.25% off its target price of $1.25 and the current market capitalization stands at $4.26M. The recent change has given its price a -33.84% deficit over SMA 50 and -95.55% deficit over its 52-week high. The stock witnessed -32.55% declines, -47.13% declines and -75.23% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JAGX’s volatility during a week at 13.96% and during a month it has been found around 10.9%.Jaguar Health, Inc. (JAGX) Top Holders
Institutional investors currently hold around $1 million or 20.4% in JAGX stock. Look at its top three institutional owners: Invesco Ltd. owns $299 thousand in Jaguar Health, Inc., which represents roughly 7.02% of the company’s market cap and approximately 29.9% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 1,311,580 shares of the stock are valued at $218 thousand. The third largest holder is Burford Capital Investment Management Llc, which currently holds $205 thousand worth of this stock and that ownership represents nearly 4.81% of its market capitalization.Jaguar Health, Inc. 13F Filings
At the end of December reporting period, 7 institutional holders increased their position in Jaguar Health, Inc. (NASDAQ:JAGX) by some 2,056,879 shares, 6 decreased positions by 93,822 and 5 held positions by 3,099,646. That puts total institutional holdings at 5,250,347 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 2,003,709 shares while 2 institutional investors sold out their entire positions totaling 29,818 shares.
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company’s animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar’s non-prescription product for total gut health in equine athletes.